Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

Bipolar androgen therapy (BAT) results in rapid fluctuation of testosterone (T) between near-castrate and supraphysiological levels and has shown promise in metastatic castration-resistant prostate cancer (mCRPC). Its clinical effects may be mediated through induction of DNA damage, and preclinical studies suggest synergy with PARP inhibitors.

Patients and methods

This was a single-center, Phase II trial testing olaparib plus BAT (T cypionate/enanthate 400 mg every 28 days) with ongoing androgen deprivation. Planned recruitment was 30 subjects (equal proportions with/without homologous recombination repair [HRR] gene mutations) with mCRPC post abiraterone and/or enzalutamide. The primary objective was to determine PSA₅₀ response (PSA decline ≥50% from b

SUBMITTER: Schweizer MT 

PROVIDER: S-EPMC10286318 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature